In this article, we revisit the many twists and turns of the aducanumab clinical trials and explore the scientific community's response to the latest analysis of the data.READ MORE
In our latest interview series, we discuss the potential of psychedelics to revolutionize clinical neuroscience with thought leaders in the field. In this first interview of our series exploring the Neuroscience of Psychedelics, we talk to Johns Hopkins Associate Professor Gul Dölen, who has spent years exploring the effects of MDMA on the mammalian (and more recently, cephalopod) brain.
Neuroscience 2019, the world’s biggest conference of brain science, finished just over a month ago. In the wake of some particularly inflammatory headlines, we take a closer look at whether claims that new model systems for studying the brain could produce sentience in a jar have any truth to them.
At SfN 2019, we interviewed Li-Huei Tsai, director of the Picower Institute for Learning and Memory, to take a deeper look at the field of non-invasive brain stimulation and hear why it has such a substantial therapeutic promise.READ MORE
Could therapies targeting our immune system help treat Alzheimer's disease by flipping long-standing research theories on their head? A new drug targeting a two-faced protein is currently undergoing clinical trials to find an answer.READ MORE
In this interview, conducted at the Neuroscience 2019 conference, we talk with DeepLabCut’s co-creator, Dr Mackenzie Mathis, a principal investigator at Harvard’s Rowland Institute, about open science, DeepLabCut’s potential for prosthetics, and how to safeguard against automated software being used for the wrong reasons.
In this article, we will take an in-depth look at fibromyalgia: what it is, what causes it, and how researchers recommend finding relief.
What do we mean by lab of the future? What innovations are required to get there? These are the key themes explored by this year's Lab of the Future Congress, summarized in this article.READ MORE
Effective treatments for post-traumatic stress disorder (PTSD) have proved extremely elusive to researchers. For some, the legalisation of cannabis could present an opportunity to develop new therapies for PTSD.We talked to Allied Corp’s CEO Calum Hughes about cannabis’s potential for PTSD therapeutics.
A new phase of a research project has asked for help from the public in the fight against the fatal neurological condition Huntington’s disease (HD).READ MORE